184 related articles for article (PubMed ID: 38566988)
1. Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma.
Lin X; Guan T; Xu Y; Li Y; Lin Y; Chen S; Chen Y; Wei X; Li D; Cui Y; Lin Y; Sun P; Guo J; Li C; Gu J; Yang W; Zeng H; Ma C
Front Immunol; 2024; 15():1337489. PubMed ID: 38566988
[TBL] [Abstract][Full Text] [Related]
2. CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma.
Liu T; Dai X; Xu Y; Guan T; Hong L; Zaib T; Zhou Q; Cheng K; Zhou X; Ma C; Sun P
J Transl Med; 2023 Oct; 21(1):710. PubMed ID: 37817249
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma.
Lin X; Guan T; Li Y; Lin Y; Huang G; Lin Y; Sun P; Li C; Gu J; Zeng H; Ma C
Front Immunol; 2024; 15():1337557. PubMed ID: 38390321
[TBL] [Abstract][Full Text] [Related]
4. CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs.
Xiong G; Chen Z; Liu Q; Peng F; Zhang C; Cheng M; Ling R; Chen S; Liang Y; Chen D; Zhou Q
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724465
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models.
Xuan Y; Sheng Y; Zhang D; Zhang K; Zhang Z; Ping Y; Wang S; Shi X; Lian J; Liu K; Zhang Y; Li F
Transl Oncol; 2021 Aug; 14(8):101138. PubMed ID: 34052626
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
[TBL] [Abstract][Full Text] [Related]
8. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
9. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
Li Y; Hermanson DL; Moriarity BS; Kaufman DS
Cell Stem Cell; 2018 Aug; 23(2):181-192.e5. PubMed ID: 30082067
[TBL] [Abstract][Full Text] [Related]
10. Implication of Highly Cytotoxic Natural Killer Cells for Esophageal Squamous Cell Carcinoma Treatment.
Lim KS; Mimura K; Kua LF; Shiraishi K; Kono K
J Immunother; 2018; 41(6):261-273. PubMed ID: 29683892
[TBL] [Abstract][Full Text] [Related]
11. Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells.
Tang SY; Zha S; Du Z; Zeng J; Zhu D; Luo Y; Wang S
Stem Cell Res Ther; 2021 Nov; 12(1):580. PubMed ID: 34802459
[TBL] [Abstract][Full Text] [Related]
12. CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma.
Yue G; Tang J; Zhang L; Niu H; Li H; Luo S
J Gastrointest Oncol; 2021 Feb; 12(1):38-51. PubMed ID: 33708423
[TBL] [Abstract][Full Text] [Related]
13. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
[TBL] [Abstract][Full Text] [Related]
14. CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
Timpanaro A; Piccand C; Dzhumashev D; Anton-Joseph S; Robbi A; Moser J; Rössler J; Bernasconi M
J Exp Clin Cancer Res; 2023 Nov; 42(1):293. PubMed ID: 37924157
[TBL] [Abstract][Full Text] [Related]
15. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells.
Klaihmon P; Kang X; Issaragrisil S; Luanpitpong S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445684
[TBL] [Abstract][Full Text] [Related]
16. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
[TBL] [Abstract][Full Text] [Related]
17. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
Goldenson BH; Hor P; Kaufman DS
Front Immunol; 2022; 13():841107. PubMed ID: 35185932
[TBL] [Abstract][Full Text] [Related]
18. A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma.
Wang L; Wang X; Wu Y; Wang J; Zhou W; Wang J; Guo H; Zhang N; Zhang L; Hu X; Zhao Y; Miao J; Zhang Z; Chard Dunmall LS; Zhang D; Lemoine NR; Cheng Z; Wang Y
Cancer Lett; 2023 Aug; 568():216303. PubMed ID: 37422126
[TBL] [Abstract][Full Text] [Related]
19. CD276 promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma through the TGF-β/SMAD signaling.
Zhang X; Xu C; Wang C; Pei Y; He M; Wan Z; Hou J; Wang L
Clin Exp Metastasis; 2024 Apr; 41(2):81-90. PubMed ID: 38396262
[TBL] [Abstract][Full Text] [Related]
20. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
